Background
==========

The prognostic significance of *TP53*mutations in breast cancer has been investigated in several studies, but the independency of *TP53*towards other prognostic factors and the nature of the mutations that may carry a worse prognosis are still unclear.

Methods
=======

Retrospective series of breast cancer cases from 10 hospitals in seven different European countries were combined to assemble a large dataset of clinical and molecular data on 1794 European women with primary breast cancer who were followed-up for 10 years, and whose tumor had been screened for *TP53*mutation by gene sequencing. The association between *TP53*gene mutation and breast-specific cancer death was examined in univariate and multivariate models including classical prognostic factors of survival.

Results
=======

*TP53*gene mutations were more frequent in tumors of ductal and medullar types, aggressive phenotype (high grade, large size, node-positive cases and low hormone receptor contents) and in women under 60 years old. An elevated risk of breast-specific cancer death within 10 years of follow-up was found in patients with a *TP53*mutation within exons 5--8 in their tumor compared with patients with no such mutation (relative risk, 2.27; *P*\< 0.0001). This association remained valid after adjustment for tumor size, nodes status and hormone receptor contents. An interaction between *TP53*gene mutation and PR content was found, patients with *TP53*mutation and negative PR status having a very bad prognosis independently of tumor size, node status and ER status. More importantly, in patients with PR-positive status, *TP53*mutation was associated with a strong reduction in survival over 10 years. Among specific types of *TP53*mutations, non-missense mutations and missense mutations in the DNA-binding surface (L2/L3 and LSH motifs) had a worse prognosis than mutations outside the DNA-binding surface. Among missense mutations, those at codon 179 and the R248W mutant were associated with the highest mortality rates.

Conclusion
==========

These results clearly show that *TP53*gene mutation is an independent factor of prognosis in breast cancer, and advocate its use in clinical practice to improve cancer management.
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